Literature DB >> 35026576

Reconstruction of tissue-specific genome-scale metabolic models for human cancer stem cells.

Tânia Barata1, Vítor Vieira2, Rúben Rodrigues2, Ricardo Pires das Neves3, Miguel Rocha4.   

Abstract

Cancer Stem Cells (CSCs) contribute to cancer aggressiveness, metastasis, chemo/radio-therapy resistance, and tumor recurrence. Recent studies emphasized the importance of metabolic reprogramming of CSCs for the maintenance and progression of the cancer phenotype through both the fulfillment of the energetic requirements and the supply of substrates fundamental for fast-cell growth, as well as through metabolite-induced epigenetic regulation. Therefore, it is of paramount importance to develop therapeutic strategies tailored to target the metabolism of CSCs. In this work, we built computational Genome-Scale Metabolic Models (GSMMs) for CSCs of different tissues. Flux simulations were then used to predict metabolic phenotypes, identify potential therapeutic targets, and spot already-known Transcription Factors (TFs), miRNAs and antimetabolites that could be used as part of drug repurposing strategies against cancer. Results were in accordance with experimental evidence, provided insights of new metabolic mechanisms for already known agents, and allowed for the identification of potential new targets and compounds that could be interesting for further in vitro and in vivo validation.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimetabolites; Cancer Stem Cells (CSCs); Genome-Scale Metabolic Models (GSMMs); Transcription Factors (TFs); miRNAs

Mesh:

Substances:

Year:  2021        PMID: 35026576     DOI: 10.1016/j.compbiomed.2021.105177

Source DB:  PubMed          Journal:  Comput Biol Med        ISSN: 0010-4825            Impact factor:   4.589


  1 in total

1.  Integration of omics data to generate and analyse COVID-19 specific genome-scale metabolic models.

Authors:  Tadeja Režen; Alexandre Martins; Miha Mraz; Nikolaj Zimic; Damjana Rozman; Miha Moškon
Journal:  Comput Biol Med       Date:  2022-03-23       Impact factor: 6.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.